The dataset is publicly available using the following DOI: [10.6084/m9.figshare.12659813](https://doi.org/10.6084/m9.figshare.12659813)

Introduction {#sec005}
============

HIV-2 is responsible for a localized AIDS epidemic that mainly affects the West African region \[[@pone.0236642.ref001]--[@pone.0236642.ref003]\]. The therapeutic strategy for people living with HIV-2 remain challenging, due to the intrinsic resistance of this virus to non-nucleoside reverse transcriptase inhibitors (NNRTI) and fusion inhibitors, as well as the suboptimal response to some protease inhibitors (PI) \[[@pone.0236642.ref004]--[@pone.0236642.ref006]\].

In absence of randomized controlled trial, there is no consensus on the therapeutic care of people living with HIV-2 \[[@pone.0236642.ref007],[@pone.0236642.ref008]\]. The previous national ART guidelines of West African countries, online with WHO 2010 guidelines, recommended the initiation of a boosting lopinavir/r-based regimen as the preferred option or a three-NRTI based regimen as alternative \[[@pone.0236642.ref009]\]. The current British, French and USA antiretroviral (ART)-guidelines recommend initiating two NRTI associated with one boosted PI or with one integrase strand-transfer inhibitor (INSTI), and excluded the use of three NRTI as first-line regimen in patients living with HIV-2 \[[@pone.0236642.ref010]--[@pone.0236642.ref012]\]. More recently, the 2019 WHO guidelines recommended Dolutegravir (DTG) in combination with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone as the preferred first-line regimen for people initiating ART, thus without any difference between those living with HIV-1 and HIV-2 \[[@pone.0236642.ref013]\]. However, the implementation of this recommendation in low- and middle-income countries, especially those with double circulation of HIV-1 and HIV-2 is ongoing slowly and DTG-based regimen were mainly prescribed to third-line patients in referral centers \[[@pone.0236642.ref014]\].

In case of virologic failure, HIV-2 patients were enrolled for three months in an enhanced adherence counselling program. If at the end of this period the viral load remained unsuppressed, the patient was eligible to switch treatment. In 2016, West African and European guidelines on the management of treatment failure recommended for HIV-2 patients initially receiving three NRTIs or a LP/r-based regimen as first line, to switch to darunavir (DRV) or raltegravir (RAL) / Dolutegravir (DTG) in combination with NRTI backbone \[[@pone.0236642.ref014]\]. With the recent recommendation of DTG as preferred first-line regardless of HIV type, the preferred second line recommended by WHO and currently endorsed by West African countries is now LP/r based regimen for HIV-2 patients \[[@pone.0236642.ref013]\].

Thus management of virologic failure in HIV-2 patients remain challenging despite the guidelines revision, due to the limited options (NRTI, boosted PI) available, while an increasing number of studies reported virologic failure and resistance-associated mutations to NRTIs, PIs and RAL \[[@pone.0236642.ref015]--[@pone.0236642.ref021]\]. These multiple resistances jeopardize the efficacy of second line HIV-2 treatment, with multidrug resistance needing boosted darunavir plus raltegravir based regimen in resource-limited settings where HIV-2 viral load and genotypic resistance tests are neither routinely available nor affordable.

There is few data reporting experience of therapeutic care and describing long-term outcome of HIV-2-infected individuals experiencing virologic failure in resource-limited settings. Such data will be useful to orient clinicians and decision makers in the management of treatment switches in HIV-2 patients with treatment failure. This survey aimed to describe the sequence of ART regimens use, and the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses in Côte d'Ivoire.

Materials and methods {#sec006}
=====================

Study design, population and settings {#sec007}
-------------------------------------

A clinic-based cohort study was initiated in January 2012 within the International epidemiological Database to evaluate AIDS (IeDEA) in West Africa \[[@pone.0236642.ref022]\]. The eligibility criteria for this cohort were assessed during a cross-sectional survey conducted to describe virologic failure and drug resistance mutations among HIV-2-infected individuals receiving ART and followed up in six HIV clinics in Abidjan, Côte d'Ivoire \[[@pone.0236642.ref015]\]. Based on the results of this cross-sectional survey presented elsewhere \[[@pone.0236642.ref015]\], adults living with HIV-2, experiencing virologic failure, and harboring at least one drug resistance mutation, were included and followed up from 2012 to 2017.

Ethics consideration {#sec008}
--------------------

The protocol of the IeDEA west Africa collaboration cohort was reviewed and approved in Côte d'Ivoire by the National Ethic Committee for life Science and Health (CNESVS: IORG00075). Prior to the initial enrolment in the cohort, each participant was given comprehensive information on the study protocol and procedures, and had to provide a written consent before being included.

HIV-2 standard of care in Côte d'Ivoire {#sec009}
---------------------------------------

According to the national guidelines of Côte d'Ivoire at the time of study in 2012, ART was initiated in people living with HIV symptomatic stage 3--4 or asymptomatic with CD4 \<350 cells/mm^3^. In case of HIV-2 or HIV1&2, the preferred first line option was 2 NRTI plus boosted Lopinavir. Three-NRTI-based regimen was considered as alternative option (if CD4 cell counts \> 200 cells/mL or Lopinavir contraindication/intolerance) \[[@pone.0236642.ref014]\]. In case of virologic failure, HIV-2 patients should receive the most appropriate ART regimen available, with the guidance of the national referral center for adults living with HIV (Unit of Infectious and Tropical Diseases Treichville University teaching hospital) \[[@pone.0236642.ref014]\].

Study procedures {#sec010}
----------------

The follow-up consisted in the administration of a standardized questionnaire allowing collection of clinical (AIDS events and Non-AIDS severe morbidity), biological (CD4 count, viral load) and therapeutic (switches second line, salvage ART regimen) data, during routine follow-up visits.

Biological procedures {#sec011}
---------------------

A comprehensive description of the biological procedure has been published \[[@pone.0236642.ref015]\]. Briefly, virologic failure was defined as plasma HIV-2 RNA above 50 copies/mL using a real-time PCR assay \[[@pone.0236642.ref023]\]. Genotypic resistance tests (protease and reverse transcriptase sequencing) were performed using an in-house method \[[@pone.0236642.ref015]\]. The interpretation was based on the HIV French resistance algorithm update of September 2017, available at <http://www.hivfrenchresistance.org/index.html>. A genotypic susceptibility score (GSS) was generated for each patient based on the results of genotypic analyses. In 2017, a blood sample was collected from each participant presenting at the HIV clinic, for a routine follow-up visit or returning to care after a successful tracking process. This blood samples allowed performing a viral load and an additional CD4 count.

Outcomes and variables {#sec012}
----------------------

The main outcomes considered were being alive, dead or LTFU. Considering LTFU like a proxy of death, a variable combining death and LTFU was defined.

Death was defined as being reported dead in the medical records of the HIV clinic or being declared dead by a close relative or a family member. A participant was considered alive if he presented for follow-up visit during the year 2017 or if he was successfully contacted during the active tracking process. The participants who did not showed up at HIV clinic for more than three months, were not known as alive, transferred out or deceased, and were not successfully tracked (phone calls and home visits when allowed in the initial consent form) were considered LTFU.

Statistical analyses {#sec013}
--------------------

Data analysis was conducted using STATA^®^ version 14.0, Stata Corp, College Station, Texas USA. Kaplan Meier curve was used to estimate survival rate and Logrank test was used to compare survival between the two groups.

Results {#sec014}
=======

Baseline characteristics {#sec015}
------------------------

Among the 31 participants included in the study, 28 (90.3%) were receiving a PI-based regimen, 2 (6.5%) a three-NRTI-based regimen and 1 (3.2%) a raltegravir-based regimen. The median age at enrolment was 50 years (IQR = 46--54 years) and 20 patients were men (64.5%). At enrolment, the median baseline CD4 count and viral load were 456 cells/mm^3^ (IQR = 256--751) and 3,700 c/mL (IQR = 663--7797), respectively. The initial genotypic analyses retrieved PI resistance mutations (at least one) in 26 (83.9%) participants and NRTI resistance mutations in 21 (67.7%) participants. The GSS was \<2 for 14 (45.2%) patients and \>2 for 10 (32.3%) others ([Table 1](#pone.0236642.t001){ref-type="table"}).

10.1371/journal.pone.0236642.t001

###### Follow-up characteristics of antiretroviral-experienced HIV-2-infected patients with identified resistance mutations from 2012 to 2017.

![](pone.0236642.t001){#pone.0236642.t001g}

                                                        Alive               Death/LTFU             Total                p-values                           
  ----------------------------------------------------- ------------------- ---------------------- -------------------- ------------ -------- ------------ -------
                                                        n = 17 (55%)        n = 14 (45%)           n = 31                                                  
  **Follow-up duration, months, Median \[IQR\]**        60 \[58--61\]       19 \[12--35\]          57 \[24--60\]        **0.001**                          
  **Baseline CD4 count cells/mm**^**3**^                                                                                                                   
  **Median \[IQR\]**                                    445 \[266--675\]    504 \[256--855\]       456 \[256--751\]     0.489                              
  ≤350                                                  6                   (35.3)                 5                    (35.7)       11       (35.5)       
  350--500                                              4                   (23.5)                 1                    (7.2)        5        (16.1)       
  ≥500                                                  7                   (42.2)                 7                    (50.0)       14       (45.2)       
  Missing                                               0                   (0.0)                  1                    (7.1)        1        (3.2)        
  **Last CD4 count cells/mm**^**3**^                                                                                                                       
  **Median \[IQR\]**                                    281 \[193--321\]    150 \[113--278\]       230 \[120--321\]     0.202                              
  ≤350                                                  13                  (76.4)                 11                   (78.7)       24       (77.4)       
  350--500                                              2                   (11.8)                 1                    (7.1)        3        (9.7)        
  ≥500                                                  2                   (11.8)                 1                    (7.1)        3        (9.7)        
  Missing                                               0                   (0.0)                  1                    (7.1)        1        (3.2)        
  **Viral load at inclusion c/mL**                                                                                                                         
  **Median \[IQR\]**                                    730 \[372--4103\]   5992 \[3700--16716\]   3700 \[663--7797\]   **0.007**                          
  **Viral load at closing date c/mL**                                                                                                                      
  **Median \[IQR\]**                                    859 \[0--9082\]     NA                     859 \[0--9082\]                                         
  **ARV regimen at enrollment**                                                                                                                            
  PI-based                                              17                  (100.0)                11                   (78.6)       28       (90.3)       0.568
  3 NRTI-based                                          0                   (0.0)                  2                    (14.3)       2        (6.5)        
  Raltegravir-based                                     0                   (0.0)                  1                    (7.1)        1        (3.2)        
  **ARV drug switch (at least one)**                    **12**              **(70.6)**             **9**                **(64.3)**   **21**   **(67.7)**   0.270
  To darunavir[\*](#t001fn002){ref-type="table-fn"}     0                   (0.0)                  2                    (14.3)       2        (6.5)        
  To raltegravir[\*](#t001fn002){ref-type="table-fn"}   2                   (11.8)                 1                    (7.1)        3        (9.7)        
  **Genotypic susceptibility score**                    0.933                                                                                              
  \<2                                                   8                   (47.1)                 6                    (41.9)       14       (45.2)       
  ≥2                                                    5                   (29.4)                 5                    (35.7)       10       (32.3)       
  Not available                                         4                   (23.5)                 3                    (21.4)       7        (22.5)       

IQR = interquartile range, LFTU = lost to follow-up, PI = protease inhibitor, NRTI = nucleoside reverse transcriptase inhibitor

\* = non-cumulative; NA = not available; ARV = antiretroviral.

Follow up characteristics {#sec016}
-------------------------

The cumulative follow-up duration was 1327 person-months with a median duration of 52 months (IQR = 24--59). During this period, 21 (67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an INSTI-based regimen respectively. At the censured date, 17 (55.0%) patients remained in care, while 10 (32.3%) were dead and 4 (12.9%) were LTFU. The last median CD4 count were 150 cells/mm^3^ (IQR = 117--218) and 143 cells/mm^3^ (IQR = 39--340) among patients dead and LTFU, respectively. Among those still in care during follow up, the 12, 36 and 60-months survival rates were 86.8%, 68.8% and 64.9% respectively ([Fig 1](#pone.0236642.g001){ref-type="fig"}). Neither gender (HR = 1.57, p = 0.484) nor age \>50 years (HR = 0.59, p = 0.421) were associated with mortality.

![](pone.0236642.g001){#pone.0236642.g001}

Among the 17 patients remaining in care, six (35.3%) had an undetectable viral load (\<50 c/mL) and for the 11 others, the median viral load was 4,334 \[859--87,523\] c/mL, ranging from 584 to 372,346 c/mL ([Table 2](#pone.0236642.t002){ref-type="table"}). Twelve of these patients were receiving lopinavir at time of first genotyping analysis, eight (47.1%) had a GSS \<2 and five (29.4%) a GSS \>2. Their last median CD4 count was 281 cells/mm^3^ (IQR = 209--351), not significantly different to those who died or were LTFU (p = 0.20). none of participants CD4 increased after switch or after the first virologic failure.

10.1371/journal.pone.0236642.t002

###### Five-years ART-response among HIV-2 infected patients surviving after experiencing treatment failure with identified drug resistance mutations in Côte d\'Ivoire, West Africa.

![](pone.0236642.t002){#pone.0236642.t002g}

  Patients demographics   ART Response in 2012   Genotypic analyses in 2012   ART Response in 2017                                                                                                                    
  ----------------------- ---------------------- ---------------------------- ---------------------- ----- ------- --------------------------------- ------------------------------ ---- ---------------------- ----- ---------
  PAT-S01                 51                     M                            AZT/3TC/LPV/r          106   340     M184V                             V47A, V62A                     1    ABC/3TC/LPV/r          281   859
  PAT-S02                 53                     M                            ABC/3TC/LPV/r          919   713     M184V                             I54M                           2    TDF/3TC/LPV//r         209   4,334
  PAT-S03                 56                     M                            AZT/3TC/LPV/r          675   3085    M184V, S215Y                      V47A, I82M, L90M               0    AZT/3TC/LPV/r          351   372,346
  PAT-S04                 30                     F                            AZT/3TC/LPV/r          119   663     NA                                V47A,                          NA   AZT/3TC/LPV/r          291   87,523
  PAT-S05                 58                     M                            AZT/3TC/LPV/r          545   149     NA                                Wild-Type                      NA   TDF/3TC/LPV/r          362   \-
  PAT-S06                 60                     F                            ABC/ddI/LPV/r          791   4103    M184V                             NA                             NA   TDF/3TC/LPV/r          79    13,457
  PAT-S07                 33                     M                            SQV/LPV/r              141   33287   Q151M                             I50V, I54M, L90M               0    TDF/3TC/DRV/r/RAL      214   \-
  PAT-S08                 50                     M                            ABC/3TC/SQV/r          425   8790    Q151M, K65R, K70R, M184V, K223R   V47A, I50V, I84V, L90M, L99F   0    TDF/3TC/DRV/r/RAL      69    \-
  PAT-S09                 49                     M                            ddI/ABC/LPV/r          751   1471    M184V                             V47A, L99F                     2    TDF/3TC/DRV/r          256   1,535
  PAT-S10                 54                     M                            AZT/3TC/LPV/r          357   5156    Wild-Type                         Wild-Type                      3    AZT/3TC/LPV/r          103   2,337
  PAT-S11                 60                     M                            ABC/ddI/LPV/r          445   3016    Q151M, M184V, S215F               I54M, I84V                     0    ABC/ 3TC/ TDF/ DRV/r   193   9,082
  PAT-S12                 50                     M                            TDF/FTC/LPV/r          606   193     M184I                             Wild-Type                      2    ABC/3TC/LPV/r          120   \-
  PAT-S13                 53                     M                            AZT/3TC/LPV/r          157   395     M184V                             V47A                           1    AZT/3TC/LPV/r          297   223,827
  PAT-S14                 43                     F                            TDF/FTC/LPV/r          336   91      M184V                             Wild-Type                      2    TDF/3TC/LPV/r          774   \-
  PAT-S15                 55                     M                            AZT/3TC/LPV/r          712   372     NA                                V47A                           NA   AZT/3TC/ DRV/r         855   \-
  PAT-S16                 53                     M                            AZT/3TC/LPV/r          266   730     M184V, S215Y                      V47A, V62AI                    0    AZT/3TC/LPV/r          321   584
  PAT-S17                 49                     F                            TDF/FTC/LPV/r          466   5146    K65R, N69S, M184V                 V47A                           0    TDF/3TC/LPV/r          292   685

NA: Not amplified; ID = participant identifier; ART = antiretroviral therapy; VL = viral load; NRTI = Nucleoside reverse transcriptase inhibitors; PI = protease inhibitors; GSS = genotypic susceptibility score

Among the 10 patients declared dead, 6 (60.0%) had CD4 count \<200 cells/mm^3^, 7 (70.0%) had a boosted PI in their last known ART regimen, five (50.0%) had a GSS \<2 and 7 (70.0%) changed at least one drug in their ARV regimen at least once after the diagnosis of drug resistance mutation. Regarding treatment, 5 of them switched to an unappropriated and non-effective ART regimen according to the genotypic resistance test. three of them were maintained on boosted-lopinavir as a compassionate treatment until they died. Two of them received a non-recommended regimen for HIV-2 based on Atazanavir although LPV/r-based regimen was effective.

Discussion {#sec017}
==========

In this observational cohort study conducted in Côte d'Ivoire, we reported after 5 years of diagnosis of at least one drug resistance mutation to first-line ART regimen among HIV-2 patients, high mortality and lost to follow-up. Half of HIV-2 patients were not retained in care 5 years after the diagnosis of drug resistance mutation.

This high rate of mortality could be explained by the lack of access to second-line therapy for these patients in resource-limited settings. According to the US and French ART guidelines, only integrase inhibitors such as raltegravir, elvitegravir or dolutegravir or the CCR5 antagonist maraviroc (MVC) could be used as a second-line therapy among HIV-2 patients \[[@pone.0236642.ref024]--[@pone.0236642.ref028]\]. However, in most west African countries, these antiretroviral molecules are still scarcely available. In our study only three (9.3%) patients diagnosed with drug resistant viruses switched to the INSTI raltegravir, none of them received dolutegravir. Among the patients dead or LTFU, only one (7.1%) and two (14.2%) switched to an INSTI and to the PI darunavir, respectively. For these latter patients, the median last known CD4 count was 150 cells/mm^3^, indicating that more than half of them were in advanced HIV disease according to the immunologic definition \[[@pone.0236642.ref029]\]. Increase the availability of more efficient antiretroviral drugs like integrase inhibitors is critical for patients living with HIV-2 for whom the therapeutic arsenal is limited specifically for patients harboring viruses with drug resistance mutations \[[@pone.0236642.ref015]\].

In resource-limited settings, there was no clear sequence of ART regimen use for the treatment of HIV-2-infected individual experiencing virologic failure \[[@pone.0236642.ref014]\]. This lack of clear guidelines may be the consequence of limited data on the switch of treatment among HIV-2-infected patients, the lack of routine implementation of validated tool for viral load monitoring, the absence of definition of immunological failure and the paucity of data regarding drug resistance mutations \[[@pone.0236642.ref007],[@pone.0236642.ref008],[@pone.0236642.ref023],[@pone.0236642.ref030]--[@pone.0236642.ref032]\]. Since the mortality remains high among HIV-2 patients receiving ART \[[@pone.0236642.ref033],[@pone.0236642.ref034]\], it is critical to address all the gaps and need in terms of data in order to propose clear guidelines for the treatment of HIV-2 patients experiencing virologic failure.

In the present study, six of the 17 patients remaining in care had no active antiretroviral drug in their regimen. In fact, salvage regimen for those patients with a good GSS should use boosted-darunavir and DTG which remains active in some cases of resistance to the first generation of INSTI \[[@pone.0236642.ref021],[@pone.0236642.ref035]\]. Thus, in this context, genotypic resistance tests are needed in order to prevent DTG from being functional monotherapy which will result to the selection of DTG resistances. Unfortunately, according to the GSS of the patients of the present study it seems that DTG will not be sufficient and additional new drugs are needed, such as maraviroc or broad-spectrum neutralizing antibodies (Ibalizumab) \[[@pone.0236642.ref036]--[@pone.0236642.ref038]\]. Unfortunately, in our study population, among the 10 patients with no active ARV drug (GSS = 0), four died, arguing for the need of new therapeutic options for HIV-2 infection.

Since 2018, WHO guidelines recommend tenofovir plus lamivudine plus dolutegravir based regimen as the preferred first-line option according to expert opinion, pilot studies and in vitro data \[[@pone.0236642.ref039]\]. This will change the management of HIV-2-infected patients with the use of boosted-PI such as lopinavir or darunavir with an optimized NRTI-backbone in second-line \[[@pone.0236642.ref021],[@pone.0236642.ref027],[@pone.0236642.ref039]--[@pone.0236642.ref041]\]

Study limitations and strengths {#sec018}
-------------------------------

Although the study was conducted in the HIV clinics with a proper documentation of patient's follow-up, the main limitation is the lack of documentation of the cause of death. For all the patients who were not reported dead at the HIV clinic, it was not possible to identify the clinical cause of death, as the only information available in the official death certificate was "disease". In addition, viral load measurement was not routinely performed and only two measures (2012 and 2017) were available for the analysis, making it impossible to describe the evolution according to the switches of antiretroviral drugs during the five years of follow-up. Furthermore, this study presents data of a small population and the estimates may suffer from lack of statistic power. However, to our knowledge, this is one of the first report on treatment outcomes among HIV-2 patients who experienced virologic failure with at least one drug resistance mutation in West Africa. Data on long-term follow-up among HIV-2 patients are also limited and this study highlights the challenge to determine the sequence of ART use in this population.

Conclusions {#sec019}
===========

Our data call for the urgent access to second-line and third-line therapy among HIV-2 patients. Clinical trials for HIV-2-infected patients harboring multi-drug resistant viruses should be conducted in both resource-limited settings and western countries. Results from the first randomized controlled trial on HIV-2 (FIT-2) Expected in 2020, will be helpful to define a sequence of ART initiation among HIV-2 patients.

We would like to warmly thank Drs Denise Dekpanou; Albert Minga; Eugène messou; Zelika Diallo and Serge Kooley for their contribution during the implementation of the study, as well as Mr Azany Jean Claude for his strong support in data management and study monitoring and Dr Boni Simon for his support to the clinical monitoring and critical review of the manuscript.

ART

:   Antiretroviral therapy

GSS

:   Genotypic susceptibility score

HIV-2

:   Human immune deficiency virus type 2

IeDEA

:   International epidemiologic database to evaluate AIDS

LTFU

:   Lost to follow up

NNRTI

:   Non-nucleoside reverse transcriptase inhibitors

NRTI

:   Nucleoside reverse transcriptase inhibitors

PI

:   Protease inhibitors
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Reviewer \#2: The study titled "Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'lvoire West Africa" describes the various treatment modalities received by patients infected with HIV-2 experiencing virologic failure in six HIV clinics in Cote d'lvoire and the 5-year outcome of these HIV-2 patients harboring drug-resistant viruses. This study stresses on the need for clear treatment guidelines for virologic failure in HIV-2 infection and calls for an increased access to second-line and third-line drugs for HIV-2 patients in resource-limited settings.

Comments

1\. In the abstract, lines 61 and 62, the authors have mentioned that "The survival rate of HIV-2 ART-experienced patients with drug resistant viruses is somewhat low." Please accurately describe "somewhat low" based on the study's results. Also, please mention what this is in comparison to.

2\. The introduction overall is very short and not detailed. The following comments pertain to the introduction:

a\. In the second paragraph, the authors talk about the current British, French and USA ART guidelines but for comparison with West African and WHO guidelines, the authors have utilized previous West African and 2010 WHO guidelines. Please include the current WHO and West African ART guidelines here.

b\. In the next paragraph, the authors go on to conclude that "ARV optimal combination in case of virologic failure is not clear." Please elaborate on what the current guidelines are regarding virologic failure are before moving on to discuss the lack of clarity of the guidelines.

c\. In line 92, it is unclear what the authors mean by "sequencing of ART regimens". Please clarify the same in all the subsequent places where this is mentioned.

d\. The authors may consider describing further the importance of this study and how this study may impact the field.

3\. In the results section, in lines 179 and 180, the authors observed that among the 17 patients, "6 had undetectable viral loads (\<50 c/mL)". However, the authors go on to note that the viral loads "for the 11 others" (implying that these 11 patients had detectable viral loads) range from "0 to 372,346 c/mL". This is misleading as undetectable viral loads are described as \<50 c/mL but the viral loads of the 11 patients that were detected ranged starting from 0 c/mL. Please clarify.

4\. In lines 225-228, the authors declare certain factors to be the cause for the lack of clear guidelines for the treatment of HIV-2 infected individuals experiencing virologic failure. Since these factors have not been evaluated in this study, please cite a reference or indicate how the authors reached to this conclusion. If this is a speculation and the authors are calling for further studies to evaluate these factors, please indicate so appropriately.

5\. In line 233, the authors have stated that 5 patients had no active antiretroviral drug in their regimen. However, in line 241, the authors have stated "4 out of 6 patients with no active ARV drug have died." Please clarify whether it is 5 or 6 patients who had no active antiretroviral drugs in their regimen.

6\. The authors may consider citing outcome in HIV-2 infected patients who do not harbor drug resistant viruses, for comparison, in order to make their results more meaningful.

7\. There are numerous minor grammatical errors throughout the paper. Some sentences do not convey their intended meaning. Please have these edited.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

The analysis is based on 5--years outcomes of HIV-2 infected patients harboring drug resistance mutations in Cote d\'Ivoire. This study included a small number of patients, compared with similar studies recently published. Many publications debated on this subject, most of them focusing on HIV-1 patients, but only a few articles discussed HIV-2 patients and the detection of drug resistance mutations.

A major concern is the lack of statistical comparison in table 1 between the two categories of patients (alive and death) (ex. chi-squared test). Thus, the study has a practical utility, as it fills in information gaps concerning disease evolution under ARV therapy in this category of patients in resource-limited settings but it needs some revisions.

Author's response: We thank the reviewer for this encouraging comment regarding the practical utility of the study. Despite the low population size, we perform krouska wallis test to compare medians and Fischer Exact test to compare means and provide the p-values in table 1 in the revised manuscript.

Reviewer \#2:

The study titled "Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'lvoire West Africa" describes the various treatment modalities received by patients

infected with HIV-2 experiencing virologic failure in six HIV clinics in Côte d'lvoire and the 5-years outcome of these HIV-2 patients harboring drug-resistant viruses. This study stresses on the need for clear treatment guidelines for virologic failure in HIV-2 infection and calls for an increased access to second-line and third-line drugs for HIV-2 patients in resource-limited

Comments

1\. In the abstract, lines 61 and 62, the authors have mentioned that "The survival rate of HIV-2 ART-experienced patients with drug resistant viruses is somewhat low." Please accurately describe "somewhat low" based on the study's results. Also, please mention what this is in comparison to.

Author's response: We thank the reviewer for this comment, we reviewed the sentence and specified the comparison factor as follows:

The 36-months survival rate among ART-experienced HIV-2 patients with drug-resistant viruses is below 70%, lower than in HIV-1.

2\. The introduction overall is very short and not detailed. The following comments pertain to the introduction:

a\. In the second paragraph, the authors talk about the current British, French and USA ART guidelines but for comparison with West African and WHO guidelines, the authors have utilized previous West African and 2010 WHO guidelines. Please include the current WHO and West African ART guidelines here.

Author's response: We thank the reviewer for this comment; we reviewed the section to include the current WHO and West African ART guidelines here as follows:

More recently, the 2019 WHO guidelines recommended Dolutegravir (DTG) in combination with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone as the preferred first-line regimen for people initiating ART, thus without any difference between those living with HIV-1 and HIV-2 (13).. However, the implementation of this recommendation in low- and middle-income countries, especially those with double circulation of HIV-1 and HIV-2 is ongoing slowly and DTG-based regimen were mainly prescribed to third-line patients in referral centers (14).

b\. In the next paragraph, the authors go on to conclude that "ARV optimal combination in case of virologic failure is not clear." Please elaborate on what the current guidelines are regarding virologic failure are before moving on to discuss the lack of clarity of the guidelines.

Author's response: We thank the reviewer for this comment. We reviewed the section to elaborate on what the current guidelines state regarding virologic failure in the study setting and we clarified the sentence regarding clarity of guidelines.

In case of virologic failure, HIV-2 patients were enrolled for three months in an enhanced adherence counselling program. If at the end of this period the viral load remained unsuppressed, the patient was eligible to switch treatment. In 2016, West African and European guidelines on the management of treatment failure recommended for HIV-2 patients initially receiving three NRTIs or a LP/r-based regimen as first line, to switch to darunavir (DRV) or raltegravir (RAL) / Dolutegravir (DTG) in combination with NRTI backbone (14). With the recent recommendation of DTG as preferred first-line regardless of HIV type, the preferred second line recommended by WHO and currently endorsed by West African countries is now a LP/r based regimen for HIV-2 patients (13).

c\. In line 92, it is unclear what the authors mean by "sequencing of ART regimens". Please clarify the same in all the subsequent places where this is mentioned.

Author's response: We thank the reviewer for this comment, highlighting this typo. We wanted to express the idea that the sequence of use of available ART regimens for HIV-2 patients was not clearly defined and thus admitted by the clinicians and researchers. The typo introduces a confusion between sequencing that applies for the biological genotyping procedure and the sequences meaning the treatment steps during the process of ART management. We reviewed the updated version of the manuscript to use sequencing and sequence when appropriated.

d\. The authors may consider describing further the importance of this study and how this study may impact the field.

Author's response: We thank the reviewer for this comment. We have added in the introduction a sentence describing how this study may impact the field, especially the clinical practice in African countries where HIV-2 circulates.

3\. In the results section, in lines 179 and 180, the authors observed that among the 17 patients, "6 had undetectable viral loads (\<50 c/mL)". However, the authors go on to note that the viral loads "for the 11 others" (implying that these 11 patients had detectable viral loads) range from "0 to 372,346 c/mL". This is misleading as undetectable viral loads are described as \<50 c/mL but the viral loads of the 11 patients that were detected ranged starting from 0 c/mL. Please clarify.

Author's response: We thank the reviewer for this comment. We reviewed the numerical figures and corrected the mistake. This was corrected in the updated version of the manuscript as follows:

Among the 17 patients remaining in care, six (35.3%) had an undetectable viral load (\<50 c/mL) and for the 11 others, the median viral load was 4,334 \[859 - 87,523\] c/mL, ranging from 584 to 372,346 c/mL (Table 2).

4\. In lines 225-228, the authors declare certain factors to be the cause for the lack of clear guidelines for the treatment of HIV-2 infected individuals experiencing virologic failure. Since these factors have not been evaluated in this study, please cite a reference or indicate how the authors reached to this conclusion. If this is a speculation and the authors are calling for further studies to evaluate these factors, please indicate so appropriately.

Author's response: We thank the reviewer for this comment. The factors cited were illustrated with appropriate references inserted in the manuscript. We also reviewed the sentence to modulate the role of these factors as we did not evaluate them ourselves.

5\. In line 233, the authors have stated that 5 patients had no active antiretroviral drug in their regimen. However, in line 241, the authors have stated "4 out of 6 patients with no active ARV drug have died." Please clarify whether it is 5 or 6 patients who had no active antiretroviral drugs in their regimen.

Author's response: We acknowledge that the two sentences were a little bit confusing. Among the 17 patients still alive by the time of this evaluation, six had a GSS =0, meaning that they had no active drug in their regimen. In the second sentence we were highlighting the fact that in our study population, 10 out of the 31 patients with virologic failure had no effective drug in their regimen (GSS=0), and among these 10 patients, four died during the 5 years of follow up. The paragraph was updated to clarify this in the revised version of the manuscript as follows:

Unfortunately, in our study population, among the 10 patients with no active ARV drug (GSS=0), four died, arguing for the need of new therapeutic options for HIV-2 infection.

6\. The authors may consider citing outcome in HIV-2 infected patients who do not harbor drug resistant viruses, for comparison, in order to make their results more meaningful.

Author's response: We acknowledge the importance of a comparison with HIV-2 clients who do not harbor drug resistant viruses. We were unable to find comparable studies presenting survival or mortality data in HIV-2 patients according to the existence or the absence of viral resistance mutation after a long period of follow up. Most studies did not perform systematic viral load and resistance mutation testing for all the patients enrolled. We have taken good note of this comment and will consider the possibility of an ancillary study to document the outcome of the patients who did not harbor drug resistant viruses. We did not amend the revised version of the manuscript according to this comment as this sub\--study is not planned yet.

7\. There are numerous minor grammatical errors throughout the paper. Some sentences do not convey their intended meaning. Please have these edited.

Author's response: We tried our best to improve the English and the style of the manuscript with the assistance of a native English speaker.
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Dear Dr. Tchounga,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.
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If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Cristian Apetrei, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0236642.r004

Acceptance letter

Apetrei

Cristian

Academic Editor

© 2020 Cristian Apetrei

2020

Cristian Apetrei

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

24 Jul 2020

PONE-D-19-33514R1

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa

Dear Dr. Tchounga:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Cristian Apetrei

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have no competing interest to declare.

[^2]: Current address: Elizabeth Glazer Pediatric AIDS Foundation Yaoundé Office, Yaounde, Cameroon

[^3]: Current address: Agence Nationale de recherche sur le SIDA et les Hépatites, Paris, France

[^4]: Current address: Département de santé Publique, Université de Lomé, Faculté des Sciences de la santé, Lomé, Togo
